Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2021-10-25 |
Generated Narrative: Citation 5296
version: 15; Last updated: 2023-12-02 14:21:04+0000
Profile: PreprintCitation
url: Citation PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
identifier: FEvIR Object Identifier/5296, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.43
version: 2.0.0-ballot
title: PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
status: Active
date: 2021-10-25 15:17:23+0000
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description:
A preprint that has only an abstract and data is different than CT.gov results
| Code | Value[x] |
| UsageContextType program: Program | MCBK Example |
| Citation Classification Type fevir-platform-use: FEvIR Platform Use | Project Specific |
jurisdiction: World
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
author: Brian S. Alper:
summary
style: Computable Publishing
text:
Nigella Sativa Supplementation Accelerates Recovery from Mild COVID-19: First Randomized Controlled Clinical Trial (RCT) [Preprint]. Contributors: Abdulrahman E. Koshak, Emad A. Koshak, Abdullah F. Mobeireek, Mazen A. Badawi, Siraj O. Wali, Husam M. Malibary, Ali F. Atwah, Meshari M. Alhamdan, Reem A. Almalki, Tariq A. Madani. In: OSF Preprints, DOI 10.31219/osf.io/urb6f. Published August 03, 2020. Available at: https://doi.org/10.31219/osf.io/urb6f.
summary
style: APA
text:
Koshak, A. E., Koshak, E. A., Mobeireek, A. F., Badawi, M. A., Wali, S. O., Malibary, H. M., … Madani, T. A. (2020, August 3). Nigella Sativa Supplementation Accelerates Recovery from Mild COVID-19: First Randomized Controlled Clinical Trial (RCT). https://doi.org/10.31219/osf.io/urb6f
summary
style: MLA
text:
Koshak, Abdulrahman E., et al. “Nigella Sativa Supplementation Accelerates Recovery from Mild COVID-19: First Randomized Controlled Clinical Trial (RCT).” OSF Preprints, 3 Aug. 2020. Web.
summary
style: Chicago
text:
Koshak, Abdulrahman E., Emad A. Koshak, Abdullah F. Mobeireek, Mazen A. Badawi, Siraj O. Wali, Husam M. Malibary, Ali F. Atwah, et al. 2020. “Nigella Sativa Supplementation Accelerates Recovery from Mild COVID-19: First Randomized Controlled Clinical Trial (RCT).” OSF Preprints. August 3. doi:10.31219/osf.io/urb6f.
citedArtifact
identifier:
https://doi.org/10.31219/osf.io/urb6frelatedIdentifier:
https://clinicaltrials.gov/NCT04401202Titles
Type Language Text Primary title English Nigella Sativa Supplementation Accelerates Recovery from Mild COVID-19: First Randomized Controlled Clinical Trial (RCT)
Abstracts
Type Language Text Copyright Primary human use English Background Effective treatment for patients with the novel Coronavirus Disease (COVID-19) is desperately needed and is under rigorous research. Nigella sativa oil (NSO), a herbal medicine, that has a documented wide antiviral and immunomodulatory activities offering a therapeutic potential for COVID-19.
Methods Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia. They were randomly assigned to receive supplementation with oral capsules of NSO (MARNYS® Cuminmar 500 mg twice daily for 10 days) plus standard of care or standard of care medications alone. The primary endpoint was the proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization. This trial was registered with clinicaltrials.gov, NCT04401202.
Findings A total of 94 patients were enrolled. Their mean age was 35 (SD=11) years old and 57% of them were male. There were 47 patients in the treatment group (NSO) and 47 patients in the control group. The proportion of patients recovered in the treatment group was significantly higher than the control group, 37 (79%) versus 21 (45%) (p=0.001). Additionally, there was a significant difference in the average recovery time among both groups, 9 (SD=3) versus 11 (SD=3) days (p=0.003). Furthermore, 2 patients from the control group required hospitalization within the study period versus none in the treatment group. Adverse events were reported in 3 patients of NSO recipients as gastrointestinal symptoms.
Conclusions In this RCT of adult patients with mild COVID-19, NSO was associated with a significant increase in the likelihood of recovery and a decrease in the likelihood of hospitalization. To our knowledge, this is the first RCT that shows potential therapeutic benefits of NSO in patients with COVID-19 which requires further confirmation with larger double-blinded RCTs.
CC-By Attribution 4.0 International
relatesTo
type: transformed-into
classifier: FHIR Resource, Evidence
display: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Nigella Sativa Oil in Nigella Sativa for COVID-19 OSF Preprint
Documents
Url https://fevir.net/resources/Evidence/6513 resourceReference: Identifier: FEvIR Object Identifier/6513
relatesTo
type: transformed-into
classifier: FHIR Resource, Evidence
display: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Control in Nigella Sativa for COVID-19 OSF Preprint
Documents
Url https://fevir.net/resources/Evidence/6514 resourceReference: Identifier: FEvIR Object Identifier/6514
relatesTo
type: transformed-into
classifier: FHIR Resource, Evidence
display: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint
Documents
Url https://fevir.net/resources/Evidence/6512 resourceReference: Identifier: FEvIR Object Identifier/6512
publicationForm
PublishedIns
Type Title Database OSF Preprints articleDate: 2020-08-03
language: English
pageCount: 2 pages
copyright:
CC-By Attribution 4.0 International
webLocation
classifier: DOI Based
webLocation
classifier: Abstract
classification
type: Knowledge Artifact Type
classifier: Preprint
classification
type: Study Type
classifier: Randomized Controlled Trial
contributorship
Summaries
Type Source Value Author string Copied from article Abdulrahman E. Koshak, Emad A. Koshak, Abdullah F. Mobeireek, Mazen A. Badawi, Siraj O. Wali, Husam M. Malibary, Ali F. Atwah, Meshari M. Alhamdan, Reem A. Almalki, Tariq A. Madani
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change